Publications by authors named "Christopher Stroh"

Claim this Profile
C
Clinical Impact of Sub-Clonal RAS/BRAF Alterations in Liquid Biopsies From Patients With Advanced or Metastatic CRC.
Peter Gibbs, Khalid Abubaker, Danyi Wang, Zheng Feng, Jawad Hamad, Christopher Stroh

Clin Colorectal Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.
Christian Rolfo, Aurora O'Brate, Christoph Menzel, Rolf Bruns, Dilafruz Juraeva, Christopher Stroh

Clin Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients With Advanced Non-small Cell Lung Cancer Harboring MET Alterations: A Descriptive Cohort Study.
Dina Oksen, Emmanuelle Boutmy, Yuexi Wang, Christopher Stroh, Andreas Johne

Clin Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
Yi-Long Wu, Valentina Guarneri, Pei Jye Voon, Boon Khaw Lim, Jin-Ji Yang, Christopher Stroh

Lancet Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of Tepotinib in Hepatocellular Carcinoma With High-Level Amplification: Preclinical and Clinical Evidence.
Shukui Qin, Hongming Pan, Jean Frédéric Blanc, Véronique Grando, Ho Yeong Lim, Christopher Stroh

JCO Precis Oncol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B.
Xiuning Le, Luis G Paz-Ares, Jan Van Meerbeeck, Santiago Viteri, Carlos Cabrera Galvez, Christopher Stroh

Cell Rep Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Preclinical Pharmacology of Tepotinib-A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations.
Joachim Albers, Manja Friese-Hamim, Anderson Clark, Oliver Schadt, Gina Walter-Bausch, Christopher Stroh

Mol Cancer Ther· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunological and tumor-intrinsic mechanisms mediate the synergistic growth suppression of experimental glioblastoma by radiotherapy and MET inhibition.
Manuela Silginer, Eleanna Papa, Emese Szabó, Flavio Vasella, Martin Pruschy, Christopher Stroh

Acta Neuropathol Commun· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring Exon 14 Skipping.
Xiuning Le, Lingzhi Hong, Chuck Hensel, Rongrong Chen, Haley Kemp, Christopher Stroh

JCO Precis Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.
Manja Friese-Hamim, Anderson Clark, Dominique Perrin, Lindsey Crowley, Christof Reusch, Christopher Stroh

Lung Cancer· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world insights into patients with advanced NSCLC and MET alterations.
Marisa Bittoni, James Chih-Hsin Yang, Jin-Yuan Shih, Nir Peled, Egbert F Smit, Christopher Stroh

Lung Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Translational pharmacokinetic-pharmacodynamic modeling of preclinical and clinical data of the oral MET inhibitor tepotinib to determine the recommended phase II dose.
Wenyuan Xiong, Manja Friese-Hamim, Andreas Johne, Christopher Stroh, Manfred Klevesath

CPT Pharmacometrics Syst Pharmacol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations.
Linda Pudelko, Frank Jaehrling, Christof Reusch, Sanziago Vitri, Christopher Stroh

iScience· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer.
Hans Urban, Gabriele D Maurer, Anna-Luisa Luger, Nadja I Lorenz, Benedikt Sauer, Christopher Stroh

Cancers (Basel)· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tepotinib in Non-Small-Cell Lung Cancer with Exon 14 Skipping Mutations.
Paul K Paik, Enriqueta Felip, Remi Veillon, Hiroshi Sakai, Alexis B Cortot, Christopher Stroh

N Engl J Med· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping.
Ravi Salgia, Martin Sattler, Juergen Scheele, Christopher Stroh, Enriqueta Felip

Cancer Treat Rev· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Lluís Nisa, Paola Francica, Roland Giger, Matúš Medo, Olgun Elicin, Christopher Stroh

Mol Cancer Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer.
Francisco J Sánchez-Martín, Beatriz Bellosillo, Mariona Gelabert-Baldrich, Alba Dalmases, Israel Cañadas, Christopher Stroh

Clin Cancer Res· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
Eric Van Cutsem, Heinz-Josef Lenz, Claus-Henning Köhne, Volker Heinemann, Sabine Tejpar, Christopher Stroh

J Clin Oncol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgG1 anti-epidermal growth factor receptor antibodies induce CD8-dependent antitumor activity.
Jan Kubach, Mario Hubo, Christiane Amendt, Christopher Stroh, Helmut Jonuleit

Int J Cancer· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of EGFR expression level and cetuximab activity in patient-derived xenograft models of human non-small cell lung cancer.
Christiane Amendt, Eike Staub, Manja Friese-Hamim, Stephan Störkel, Christopher Stroh

Clin Cancer Res· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study.
Kenneth J O'Byrne, Ulrich Gatzemeier, Igor Bondarenko, Carlos Barrios, Corinna Eschbach, Christopher Stroh

Lancet Oncol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.
Josep Tabernero, Andres Cervantes, Fernando Rivera, Erika Martinelli, Federico Rojo, Christopher Stroh

J Clin Oncol· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer.
Annelies Debucquoy, Karin Haustermans, Anneleen Daemen, Selda Aydin, Louis Libbrecht, Christopher Stroh

J Clin Oncol· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Christopher Stroh

N Engl J Med· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis